Efficacy and safety of Tanshinone capsule in Acne vulgaris: a systematic review and meta-analysis

ObjectivesTo evaluate the efficacy and safety of Tanshinone capsule as a complementary therapy in managing of Acne Vulgaris.MethodsA systematic search of six databases was conducted to identify relevant randomized controlled trials (RCTs) from each database for nearly 20 years (from 1 Jan 2004, to 1...

Full description

Saved in:
Bibliographic Details
Main Authors: Yutong Deng, Ruli Feng, Bo Hu, Xuewen Ren, Fengchuan Zhang, Huishang Feng, Xuewan Wang, Yatong Li, Tangyunni Liu, Lingling Cai, Yuanwen Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1520039/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849391501353680896
author Yutong Deng
Ruli Feng
Bo Hu
Xuewen Ren
Fengchuan Zhang
Huishang Feng
Huishang Feng
Xuewan Wang
Yatong Li
Tangyunni Liu
Lingling Cai
Yuanwen Li
author_facet Yutong Deng
Ruli Feng
Bo Hu
Xuewen Ren
Fengchuan Zhang
Huishang Feng
Huishang Feng
Xuewan Wang
Yatong Li
Tangyunni Liu
Lingling Cai
Yuanwen Li
author_sort Yutong Deng
collection DOAJ
description ObjectivesTo evaluate the efficacy and safety of Tanshinone capsule as a complementary therapy in managing of Acne Vulgaris.MethodsA systematic search of six databases was conducted to identify relevant randomized controlled trials (RCTs) from each database for nearly 20 years (from 1 Jan 2004, to 1 June 2024). The Cochrane Handbook was used to evaluate the risk of bias. Meta-analysis was performed using Review Manager 5.4.1, and publication bias was assessed the Stata SE 12.0 software. GRADEpro was used to assess the quality of the evidence.ResultsA total of 2,969 participants from 28 studies were included. We found that Tanshinone capsules can reduce acne recurrence rates [risk ratio (RR) 0.44, 95% confidence interval (CI): 0.34 to 0.57, p < 0.00001]; downregulate levels of necrosis factor-alpha (TNF-α) [ mean difference (MD) 0.44, −10.18, 95% CI: −13.57 to −8.04, p < 0.00001], interleukin (IL) 4 (MD -6.46, 95%CI: −7.14 to −5.77, p < 0.00001), IL-6 (MD -16.14, 95%CI: −30.10 to −2.18, p = 0.02), IL-8 (MD -4.48, 95%CI: −8.30 to −0.65, p = 0.02) and testosterone (MD -14.50, 95%CI: −17.59 to −11.40, p < 0.00001); lower Global Acne Grading System (GAGS) score (MD -4.71, 95%CI: −7.62 to −1.80, p = 0.002); decrease sebum secretion rates (MD -0.29, 95%CI: −0.49 to −0.10, p = 0.003), but the regulation of Luteinizing hormone (LH), Follicle-stimulating hormone (FSH), Estradiol (E2) is not obvious. In terms of safety, the incidence of adverse events in the experimental group was less than that in the control group (RR 0.70, 95%CI: 0.56 to 0.87, p = 0.001). The Begg test and Egger test results indicated no publication bias. Furthermore, the levels of evidence ranged from very low to moderate due to risk of bias and heterogeneity.ConclusionTanshinone capsules can relieve the symptoms of acne vulgaris, regulate inflammatory cytokines and hormone levels in patients, and reduce recurrence. However, due to the limitations of this study, more multi-center and large-sample studies are needed to confirm these conclusions.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024562320, identifier CRD42024562320.
format Article
id doaj-art-9a4dce3f47f34944a9be5602be3a6d6c
institution Kabale University
issn 1663-9812
language English
publishDate 2025-03-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj-art-9a4dce3f47f34944a9be5602be3a6d6c2025-08-20T03:41:03ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-03-011610.3389/fphar.2025.15200391520039Efficacy and safety of Tanshinone capsule in Acne vulgaris: a systematic review and meta-analysisYutong Deng0Ruli Feng1Bo Hu2Xuewen Ren3Fengchuan Zhang4Huishang Feng5Huishang Feng6Xuewan Wang7Yatong Li8Tangyunni Liu9Lingling Cai10Yuanwen Li11Beijing University of Chinese Medicine, Beijing, ChinaBeijing University of Chinese Medicine, Beijing, ChinaDepartment of Dermatology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, ChinaDepartment of Dermatology, Shanxi Traditional Chinese Medical Hospital, Shanxi, ChinaDepartment of Dermatology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, ChinaDepartment of Dermatology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, ChinaDepartment of Dermatology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, ChinaBeijing University of Chinese Medicine, Beijing, ChinaBeijing University of Chinese Medicine, Beijing, ChinaBeijing University of Chinese Medicine, Beijing, ChinaDepartment of Dermatology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, ChinaDepartment of Dermatology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, ChinaObjectivesTo evaluate the efficacy and safety of Tanshinone capsule as a complementary therapy in managing of Acne Vulgaris.MethodsA systematic search of six databases was conducted to identify relevant randomized controlled trials (RCTs) from each database for nearly 20 years (from 1 Jan 2004, to 1 June 2024). The Cochrane Handbook was used to evaluate the risk of bias. Meta-analysis was performed using Review Manager 5.4.1, and publication bias was assessed the Stata SE 12.0 software. GRADEpro was used to assess the quality of the evidence.ResultsA total of 2,969 participants from 28 studies were included. We found that Tanshinone capsules can reduce acne recurrence rates [risk ratio (RR) 0.44, 95% confidence interval (CI): 0.34 to 0.57, p < 0.00001]; downregulate levels of necrosis factor-alpha (TNF-α) [ mean difference (MD) 0.44, −10.18, 95% CI: −13.57 to −8.04, p < 0.00001], interleukin (IL) 4 (MD -6.46, 95%CI: −7.14 to −5.77, p < 0.00001), IL-6 (MD -16.14, 95%CI: −30.10 to −2.18, p = 0.02), IL-8 (MD -4.48, 95%CI: −8.30 to −0.65, p = 0.02) and testosterone (MD -14.50, 95%CI: −17.59 to −11.40, p < 0.00001); lower Global Acne Grading System (GAGS) score (MD -4.71, 95%CI: −7.62 to −1.80, p = 0.002); decrease sebum secretion rates (MD -0.29, 95%CI: −0.49 to −0.10, p = 0.003), but the regulation of Luteinizing hormone (LH), Follicle-stimulating hormone (FSH), Estradiol (E2) is not obvious. In terms of safety, the incidence of adverse events in the experimental group was less than that in the control group (RR 0.70, 95%CI: 0.56 to 0.87, p = 0.001). The Begg test and Egger test results indicated no publication bias. Furthermore, the levels of evidence ranged from very low to moderate due to risk of bias and heterogeneity.ConclusionTanshinone capsules can relieve the symptoms of acne vulgaris, regulate inflammatory cytokines and hormone levels in patients, and reduce recurrence. However, due to the limitations of this study, more multi-center and large-sample studies are needed to confirm these conclusions.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024562320, identifier CRD42024562320.https://www.frontiersin.org/articles/10.3389/fphar.2025.1520039/fullTanshinone capsuleAcne vulgarismeta-analysissystematic reviewrandomized controlled trial
spellingShingle Yutong Deng
Ruli Feng
Bo Hu
Xuewen Ren
Fengchuan Zhang
Huishang Feng
Huishang Feng
Xuewan Wang
Yatong Li
Tangyunni Liu
Lingling Cai
Yuanwen Li
Efficacy and safety of Tanshinone capsule in Acne vulgaris: a systematic review and meta-analysis
Frontiers in Pharmacology
Tanshinone capsule
Acne vulgaris
meta-analysis
systematic review
randomized controlled trial
title Efficacy and safety of Tanshinone capsule in Acne vulgaris: a systematic review and meta-analysis
title_full Efficacy and safety of Tanshinone capsule in Acne vulgaris: a systematic review and meta-analysis
title_fullStr Efficacy and safety of Tanshinone capsule in Acne vulgaris: a systematic review and meta-analysis
title_full_unstemmed Efficacy and safety of Tanshinone capsule in Acne vulgaris: a systematic review and meta-analysis
title_short Efficacy and safety of Tanshinone capsule in Acne vulgaris: a systematic review and meta-analysis
title_sort efficacy and safety of tanshinone capsule in acne vulgaris a systematic review and meta analysis
topic Tanshinone capsule
Acne vulgaris
meta-analysis
systematic review
randomized controlled trial
url https://www.frontiersin.org/articles/10.3389/fphar.2025.1520039/full
work_keys_str_mv AT yutongdeng efficacyandsafetyoftanshinonecapsuleinacnevulgarisasystematicreviewandmetaanalysis
AT rulifeng efficacyandsafetyoftanshinonecapsuleinacnevulgarisasystematicreviewandmetaanalysis
AT bohu efficacyandsafetyoftanshinonecapsuleinacnevulgarisasystematicreviewandmetaanalysis
AT xuewenren efficacyandsafetyoftanshinonecapsuleinacnevulgarisasystematicreviewandmetaanalysis
AT fengchuanzhang efficacyandsafetyoftanshinonecapsuleinacnevulgarisasystematicreviewandmetaanalysis
AT huishangfeng efficacyandsafetyoftanshinonecapsuleinacnevulgarisasystematicreviewandmetaanalysis
AT huishangfeng efficacyandsafetyoftanshinonecapsuleinacnevulgarisasystematicreviewandmetaanalysis
AT xuewanwang efficacyandsafetyoftanshinonecapsuleinacnevulgarisasystematicreviewandmetaanalysis
AT yatongli efficacyandsafetyoftanshinonecapsuleinacnevulgarisasystematicreviewandmetaanalysis
AT tangyunniliu efficacyandsafetyoftanshinonecapsuleinacnevulgarisasystematicreviewandmetaanalysis
AT linglingcai efficacyandsafetyoftanshinonecapsuleinacnevulgarisasystematicreviewandmetaanalysis
AT yuanwenli efficacyandsafetyoftanshinonecapsuleinacnevulgarisasystematicreviewandmetaanalysis